To analyze the characteristics of adverse drug reaction (ADR) in a specialized stomatology hospital and thus provide references for clinical rational drug use and risk management.

Ovarian cancer is the most lethal malignancy of the female reproductive system worldwide. Chemoresistance, particularly platinum resistance, is a major factor limiting improvement in prognosis, and its underlying mechanisms involve complex regulation of and escape from multiple programmed cell death pathways in cancer cells. Disulfidptosis is triggered by high expression of solute carrier family 7 member 11 (SLC7A11) under glucose starvation and shares upstream regulatory nodes with ferroptosis. Necrosis by sodium overload is driven by sodium ion overload mediated by transient receptor potential cation channel subfamily M member 4 (TRPM4), but its role remains to be further investigated. Other programmed cell death pathways are interwoven into a dynamic regulatory network through key regulatory molecules such as tumor protein p53, the caspase family, cysteine-aspartic proteases, and glutathione. Autophagy can inhibit pyroptosis; ferroptosis and pyroptosis can synergistically amplify cell-killing effects through the reactive oxygen species/NOD-like receptor thermal protein domain-associated protein 3 axis; ferroptosis and cuproptosis share the glutathione metabolic axis; and the interaction between ferroptosis and disulfidptosis can shift from antagonism to synergy under specific metabolic stress. Ferroptosis and necrosis by sodium overload mutually promote each other through cascades involving adenosine triphosphate depletion, reactive oxygen species accumulation, and mitochondrial damage. PANoptosis can overcome cancer-cell resistance to a single mode of cell death through the simultaneous activation of multiple cell death pathways. A comprehensive review of the roles and interactive networks of various programmed cell death modalities, including disulfidptosis, necrosis by sodium overload, apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis, cuproptosis, and PANoptosis, in platinum resistance in ovarian cancer is expected to provide a solid theoretical basis and potential translational directions for reversing platinum resistance and optimizing clinical treatment strategies.

This study aimed to characterize the somatic variant candidate gene profile of patients with chemotherapy-associated aplastic anemia (CAA) and compare it with that of patients with cancer without aplastic anemia (non-AA) and primary aplastic anemia (PAA). This study included 24 patients with CAA diagnosed at Peking Union Medical College Hospital from September 2019 to May 2023 (male-to-female ratio of 3∶5; median age, 60 years). Peripheral blood samples were collected for whole-exome sequencing, and the results were compared with publicly available data of patients with non-AA and PAA. A total of 37 111 variants across 9 958 genes were detected. KEGG enrichment analysis revealed that these genes were mainly concentrated in the JAK-STAT and calcium signaling pathways (all P<0.01). Regarding human leukocyte antigen (HLA) genes, the mutation frequency of HLA-DRB1 was higher in patients with CAA than in those with non-AA cancer [false discovery rate (FDR) =0.029], whereas the mutation frequencies of HLA-A (FDR=0.082) and HLA-C (FDR=0.058) were lower than in those with PAA. For myeloid disease-related genes, compared with patients with non-AA cancer, those with CAA had higher mutation frequencies in 198 genes, including BRCA2 (FDR=0.032) and ASXL1 (FDR=0.047), and lower frequencies in SAA2 (FDR=0.049), TP53 (FDR=0.045), and PIK3CA (FDR=0.049). Compared with patients with PAA, those with CAA had higher mutation frequencies in 213 genes, including BRCA2 (FDR=0.068) and ATRX (FDR=0.072), and lower frequencies in 14 genes, including ASXL1 (FDR=0.045) and DNMT3A (FDR=0.078). In conclusion, the somatic variant profile of CAA significantly differs from that of non AA cancer and PAA: its degree of immune abnormality is higher than that in non-AA cancer but milder than that in PAA; it shows a higher potential for myeloid evolution than non-AA cancer, but its transformation mechanism is more complex than that of PAA, being influenced by multiple factors including primary tumor characteristics and myeloid gene variants.

Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy; however, systematic epidemiological studies of ICI-associated cardiovascular adverse events in China remain limited. This study aims to analyze cardiovascular adverse event signals associated with ICIs approved by the Food and Drug Administration (FDA), thereby providing evidence to support safer clinical use.

To investigate the factors influencing quality of life in patients with chemotherapy-induced peripheral neuropathy (CIPN) and to construct a risk prediction model.

Objective: To investigate the efficacy and safety of combination immunotherapy in patients with locally advanced esophageal cancer. Methods: Clinical data of 212 patients with pathologically confirmed locally advanced esophageal cancer who received definitive chemoradiotherapy without surgery at the Affiliated Cancer Hospital of Xinjiang Medical University from January 2019 to January 2024 were retrospectively collected. Follow-up ended in January 2025. Patients were divided into an immunotherapy group (IO group, n=93) and a non-immunotherapy group (Non-IO group, n=119) based on whether immune checkpoint inhibitors were combined during treatment. Propensity score matching (PSM) was used to balance intergroup differences. Cox proportional hazards regression models were applied to identify independent factors influencing progression-free survival (PFS) and overall survival (OS). Results: Before PSM, among the 212 patients, the median PFS was not reached in the IO group, while it was 27.40 months in the Non-IO group. The 1-year PFS rate was significantly better in the IO group than in the Non-IO group (82.4% vs 72.3%; HR=0.65, P=0.048). The median OS was 37.37 months in the IO group and 30.17 months in the Non-IO group, with no statistically significant difference in 1-year OS rates (86.2% vs 82.6%; HR=0.66, P=0.064). After PSM, the median PFS remained unreached in the IO group (n=68), while it was 18.43 months in the Non-IO group (n=68). The IO group maintained its advantage in 1-year PFS rate (80.6% vs 73.7%; HR=0.53, P=0.017). Regarding OS, the median OS was 37.37 months in the IO group and 30.17 months in the Non-IO group, with 1-year OS rates of 84.5% and 90.8%, respectively; the difference was not statistically significant (HR=0.74, P=0.261). Multivariable analysis showed that combination immunotherapy was associated with better PFS (HR=0.49, P=0.010), but no association with OS was observed (HR=0.68, P=0.187). Additionally, N stage and smoking status were independent factors for PFS. Compared with squamous cell carcinoma, patients with non-squamous cell carcinoma had worse OS (HR=4.33, P=0.018). In terms of safety, there were no statistically significant differences between the IO group (n=68) and the Non-IO group (n=68) in the incidence of any-grade adverse events or grade ≥3 adverse events (all P＞0.05). However, the incidence of grade ≥3 lymphocytopenia was significantly higher in the IO group than in the Non-IO group (42.6% vs 19.1%; χ²=8.82, P=0.003). Conclusion: Compared with chemoradiotherapy alone, chemoradiotherapy combined with immunotherapy improves PFS in patients with locally advanced esophageal cancer, but is associated with a higher proportion of patients with severe lymphocytopenia.

Antibody-drug conjugates (ADCs) are covalently conjugated molecules composed of a monoclonal antibody, a payload, and a linker. They represent an innovative therapeutic approach that combines the precise targeting capability of target therapies with the cytotoxic effects of chemotherapeutic agents. Given the unique molecular structure of ADCs, drug-related adverse reactions have drawn a considerable attention. Based on the safety data of ADCs currently available in the field of lung cancer, the common adverse drug reactions primarily involve the digestive system, hematologic system, hepatobiliary system, pulmonary system, skin, eyes, sensory nervous system, and musculoskeletal system. Unlike other cancer types, lung cancer is characterized by complex disease subtypes and molecular pathological mechanisms, as well as diverse treatment modalities. Moreover, patients with advanced lung cancer often have comorbidities such as chronic obstructive pulmonary disease and pulmonary inflammation, making the comprehensive management of ADC-related adverse reactions even more challenging. To address this, the Precision Treatment Branch of Thoracic Oncology, Chinese Geriatric Health Association, has taken the lead in organizing a multidisciplinary panel of domestic experts in gastroenterology, dermatology, respiratory medicine, ophthalmology and oncology, to discuss and jointly formulate the "Consensus of Chinese experts on the multidisciplinary management of adverse reactions to antibody-drug conjugates in the treatment of Lung Cancer (2025 edition)". A total of 21 recommendations are proposed in this consensus, covering pre-ADC safety assessments, comprehensive monitoring and management of relevant adverse reactions during ADC treatment, patient education, and medication guidance for special populations. The consensus aims is to provide clinicians with practical guidelines for the application of ADC, thereby maximizing therapeutic benefits for patients with lung cancer.

Carrimycin is a macrolide antibiotic widely used in the pharmaceutical and clinical fields， with its primary composition consisting of three distinct derivatives of spiramycin. For decades， macrolides like carrimycin have been valued for their efficacy against Gram-positive bacteria and certain atypical pathogens. However， as research has progressed， recent studies have revealed that carrimycin， along with various other structurally modified spiramycin derivatives， exhibits significant antitumor activity in multiple experimental models. This finding suggests that the spiramycin molecular scaffold possesses intrinsic potential beyond its conventional antibacterial role. By strategically modifying the substituents attached to this core structure， it may be feasible to develop novel compounds with enhanced and more selective antitumor properties. Despite this promising outlook， research into the specific targets and comprehensive mechanisms underlying the antitumor effects of spiramycin derivatives remains notably insufficient. A major gap exists in the precise identification of their molecular targets within cancer cells and the detailed signaling pathways they modulate. This lack of mechanistic understanding poses a substantial barrier to the rational design， optimization， and clinical translation of spiramycin-based antitumor therapeutics. To systematically address this knowledge gap and elucidate the antitumor mechanism of this compound class， the present study adopted an activity-based protein profiling （ABPP） strategy. ABPP is a chemoproteomic approach that enables the direct identification of functionally active proteins that interact with small-molecule probes in a native biological context. As a first step， we designed and synthesized a novel， high-activity spiramycin derivative termed n-hexanoyl spiramycin （h-SPM）. Building upon the structure of h-SPM， we subsequently engineered and synthesized a structurally analogous activity-based probe. This probe was specifically functionalized with chemical handles （such as an alkyne group） compatible with ABPP methodologies， allowing for downstream bioorthogonal conjugation and enrichment steps. The experimental workflow began by incubating this active probe with live cancer cells. During this co-incubation period， the probe engaged with and covalently bound to its potential protein targets within the complex cellular environment. Following the interaction， cells were lysed， and the probe-labeled proteins were efficiently isolated and purified using affinity-based enrichment techniques-specifically via copper-catalyzed azide-alkyne cycloaddition （click chemistry） to immobilize them onto a solid support. The enriched protein pool was then subjected to in-depth analysis using liquid chromatography-mass spectrometry （LC-MS）. This analytical phase yielded detailed， proteome-wide information on the identities of proteins that interact with the h-SPM-based probe. To extract biological insights from the list of identified proteins， we performed comprehensive bioinformatic analysis using Gene Ontology （GO） enrichment. This systematic classification provided crucial information regarding the biological processes， molecular functions， and cellular components associated with the captured proteins. The functional annotations derived from GO analysis allowed us to evaluate and prioritize several promising candidate target proteins for further experimental validation. Through this integrated proteomic and bioinformatic approach， we successfully identified multiple potential cellular targets of h-SPM. Notable among these were amyloid precursor protein （APP） and low-density lipoprotein receptor （LDLR）， both of which are implicated in diverse cellular processes such as cell adhesion， signal transduction， and metabolic regulation. To confirm the biological relevance of these interactions， we employed Western Blotting experiments. These studies verified that the expression or post-translational modification states of APP and LDLR were altered in response to h-SPM treatment， thereby confirming their status as responsive molecular targets. After identifying and preliminarily validating APP as a key interactor， we proceeded to investigate its functional role in the drug's mechanism of action. Using short hairpin RNA （shRNA）-mediated protein knockdown， we generated cancer cell lines with significantly reduced APP expression. Comparative analysis of drug sensitivity between these knockdown cells and their wild-type counterparts revealed a marked attenuation of h-SPM's antitumor effects in the absence of APP. Complementary to this， cell staining assays， including immunofluorescence， were conducted to visualize morphological changes， alterations in cell viability， and the subcellular localization of relevant biomarkers following h-SPM treatment. Collectively， these functional experiments provided compelling evidence that APP plays a critical and indispensable role in mediating the antitumor activity of h-SPM. Our findings thus outline a preliminary model of the drug's mechanism， likely involving cellular pathways regulated or influenced by APP. In summary， this study achieves two significant objectives. First， it establishes and validates a robust， generalizable target-screening platform based on ABPP， specifically tailored for the investigation of spiramycin-class compounds. Second， and more importantly， it delivers novel biological insights by pinpointing specific protein targets such as APP. The identification of these targets provides invaluable mechanistic clues and a solid theoretical foundation for the future development of this family of compounds. This work effectively advances spiramycin derivatives from compounds with observed phenotypic activity toward agents with an emerging mechanistic understanding， thereby paving the way for more targeted drug design and informed combination therapy strategies in oncology. Future studies will focus on delineating the detailed downstream consequences of APP engagement by h-SPM and exploring the therapeutic potential of other identified targets in preclinical models.

The rearranged during transfection (RET) gene is a proto-oncogene encoding a receptor tyrosine kinase. RET gene alterations are driver events in various tumors. Pralsetinib and selpercatinib are novel, highly selective RET tyrosine kinase inhibitors (RET-TKIs). They are recommended as priority therapeutic options for RET fusion-positive non-small cell lung cancer (NSCLC) in the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer and Thyroid Carcinoma and the Chinese Medical Association (CMA) Clinical Guidelines for Lung Cancer, as well as for radioiodine-refractory differentiated thyroid cancer with RET fusion and RET-mutant medullary thyroid carcinoma. Common adverse events asosociated with pralsetinib and selpercatinib include hypertension, liver enzyme abnormalities, neutropenia and fatigue. Studies have demonstrated that the incidence of adverse events is not associated with disease type. Given the low prevalence of RET gene alterations (＜5%), which are regarded as rare genetic mutations, clinical experience in the use pf RET-TKIs and and patient management remains limited. Base on the current status of adverse event management of RET-TKIs in China, and integrating the latest international evidence and clinical experience, the Chinese Medical Doctor Association Tumor Multidisciplinary Diagnosis and Treatment Professional Committee and the Shenzhen Medical Doctor Association Tumor Multidisciplinary Diagnosis and Treatment Professional Committee organized discussion among experts from medical oncology, respiratory medicine, radiation oncology, thoracic surgery, and other related disciplines to formulate this expert consensus on the management of adverse events of RET-TKIs.

Chemotherapy-induced myelosuppression (CIM) is a common and serious adverse reaction during chemotherapy in patients with malignant tumors. Kaempferol, an important active component of leukocyte-elevating traditional Chinese medicine, may play a role in its improvement. This study aims to explore the research status and mechanisms of kaempferol in improving CIM and to provide reference evidence for its application in the prevention and treatment of CIM.

To investigate the incidence of severe cancer therapy-related thrombocytopenia (CTRT) and associated factors in children.

Cisplatin (CDDP) is an anticancer drug widely used in clinical practice. The immunotoxic effects of CDDP residues in the environment on aquatic organisms remain unclear. This study aimed to evaluate the immunotoxic effects of CDDP at environmentally relevant concentrations on zebrafish and to verify the mediating role of the NF-κB signaling pathway. Using zebrafish as a model organism, we systematically investigated the toxicological consequences of CDDP exposure on the immune system. The results showed that CDDP significantly reduced the survival and hatching rates of zebrafish, with a median lethal concentration (LC50) of 0.48 mg/L. In addition, CDDP induced developmental retardation, eye size reduction, and other morphological abnormalities in the larvae, as well as decreased spontaneous locomotion and disrupted light-dark rhythm. In terms of oxidative stress, CDDP exposure elevated reactive oxygen species (ROS) and malondialdehyde (MDA) levels, while decreasing glutathione (GSH) content and catalase (CAT) activity, which indicated impairment of the antioxidant defense system. Immunological analyses revealed abnormal recruitment of macrophages and neutrophils, dysregulated complement C3 levels, and persistent suppression of immunoglobulin M (IgM). Long-term exposure led to altered kidney function markers in adult zebrafish. From a mechanism perspective, CDDP markedly upregulated the expression of key genes in the NF-κB signaling pathway, driving excessive immune-inflammatory responses. These effects were observable even at the environmentally relevant concentration of 0.025 mg/L. This study provides a theoretical basis for elucidating the ecological risks and immunotoxic mechanisms of CDDP in aquatic environments.

This study aimed to explore the impact of dihydroartemisinin (DHA) on cell proliferation, migration, and invasion in oral squamous cell carcinoma (OSCC). Our findings offer a theoretical foundation for advancing the research and development of novel therapeutic agents for OSCC.

To determine whether dentin sialophosphoprotein (DSPP) modulates oxaliplatin efficacy for colorectal cancer (CRC) and explore the underlying integrin αvβ3-dependent mechanism.

Objective: To exploit the elevated glutathione (GSH) levels in the tumor microenvironment and investigate the therapeutic efficacy of a novel glutathione-responsive apurinic/apyrimidinic (AP) site captor, Probe-NEt, against anaplastic thyroid cancer (ATC). Methods: Fluorescence imaging compared Probe-NEt uptake and activation in normal thyroid (Nthy ori 3-1), ATC (THJ-16T, CAL-62), and lung cancer (H1299) cells. Half maximal inhibitory concentration (IC50) values were determined by cytotoxicity assays; DNA damage was evaluated using appropriate assays. Flow cytometry analyzed cell cycle distribution and apoptosis following treatment with low (5 μmol/L) or high (20 μmol/L) Probe-NEt concentrations. BALB/c nude mice bearing subcutaneous ATC xenografts received low (0.025 mg) or high (0.05 mg) dose injections. Tumor volumes were monitored; HE staining assessed biosafety in major organs; immunohistochemistry detected apoptosis-related protein expression. Results: ATC cells demonstrated significantly higher Probe-NEt activation than normal thyroid cells. Probe-NEt exhibited selective cytotoxicity (higher IC50 in normal vs. ATC cells; all P＜0.01) with time-dependent characteristics; the selectivity ratio increased from 1.7 at 24 h (62.4 vs. 37.7 μmol/L) to 2.4 at 48 h (32.7 vs. 13.5 μmol/L). Probe-NEt induced DNA damage, G2/M arrest (THJ-16T: from 5% to 43%; CAL-62: from 19% to 37%), and dose-dependent late apoptosis. In THJ-16T cells, late apoptotic rates rose from 5.49% (control) to 13.95% (low-dose) and 63.43% (high-dose), with viable cells decreasing accordingly (89.42%, 76.01%, 20.45%). CAL-62 cells showed similar trends (16.72%, 40.19%, 69.88%). In vivo, Probe-NEt significantly suppressed tumor growth without hepatorenal toxicity (all P＞0.167). Immunohistochemistry revealed upregulated pro-apoptotic proteins, downregulated anti-apoptotic proteins, and decreased Ki-67 expression. Conclusion: The glutathione-responsive AP site captor Probe-NEt significantly inhibits ATC cell growth, induces G2/M phase cell cycle arrest, promotes late apoptosis, and exhibits high selectivity and favorable biosafety profiles.

In recent years, antibody-drug conjugates (ADCs) have achieved remarkable progress in the treatment of solid tumors and are now widely applied in malignancies such as breast cancer, ovarian cancer, cervical cancer, urothelial carcinoma, and non-small cell lung cancer, demonstrating favorable clinical efficacy. However, with their expanding clinical use, safety challenges associated with ADCs have become increasingly apparent. Among these, ocular adverse events have received limited attention in the past but is now emerging as a clinically relevant concern, as it may impair patients' quality of life and necessitate treatment modifications. Due to differences in payloads, target specificity, and mechanisms of action, various ADCs may induce ocular adverse events, including corneal disorders such as dry eye and keratoconjunctivitis, which can lead to visual disturbances, diminished quality of life, and reduced treatment adherence. Consequently, appropriate preventive and management strategies are urgently needed in clinical practice. To address this gap, and based on the latest international and domestic clinical evidence as well as multidisciplinary expert experience in oncology and ophthalmology, a Chinese expert consensus was developed following extensive discussion. This consensus aims to enhance clinicians' awareness of ADC-associated ocular adverse events, promote the safe application of ADCs in the treatment of solid tumors, and ultimately improve patients' quality of life and therapeutic outcomes.

Chemotherapy-induced neutropenia (CIN) is a common hematological adverse event and dose-limiting toxicity of chemotherapy. CIN may lead to dose reduction or delay of chemotherapeutic agents, febrile neutropenia (FN), and severe infections, which results in increased treatment costs, reduced chemotherapy efficacy, and even life-threatening complications. Therefore, standardized assessment of the risk of CIN in cancer patients, timely identification and intervention of FN, and appropriate prevention and treatment are essential to reduce CIN-related complications, improve patients' quality of life, and enhance chemotherapy outcomes. Based on the "Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition)", the Committee of Medical Oncology and the Committee of Neoplastic Supportive-care of China Anti-Cancer Association have thoroughly reviewed and summarized the latest evidence and clinical practices worldwide. This update puts forward 11 recommendations regarding the definition, grading, risk assessment, prevention, and treatment strategies for CIN, aiming to provide more timely and standardized guidance for Chinese oncologists in the diagnosis, treatment, and prevention of CIN.

Objective: To analyze the clinical characteristics of oral adverse reactions associated with novel anti-tumor drugs, providing references for early diagnosis and treatment to improve cancer patients' qualities of life and therapeutic efficacies. Methods: Clinical data and photographs of 11 tumor patients treated at Beijing Hospital from January 2020 to April 2025, who developed oral adverse reactions after receiving targeted therapy, antibody-drug conjugates (ADC), or immune checkpoint inhibitor (ICI), were collected. A retrospective analysis was conducted to summarize the clinical characteristics of these oral adverse reactions. Results: Among the 11 patients with oral adverse reactions related to novel anti-tumor drugs, 3 patients received targeted therapy alone, 1 patient received ADC alone, 1 patient received a combination of targeted therapy and ADC, and 6 patients were treated with ICI alone. The time from the first administration of the novel anti-tumor drug to the onset of oral adverse reactions ranged from 0.5 to 18.0 months. The clinical manifestations of oral adverse reactions were various, with oral mucositis (9 cases) being the most common, followed by xerostomia (7 cases), oral candidiasis (4 cases,), hemangioma (1 case), and exacerbation of a pre-existing condition (vitiligo, 1 case). Most adverse reactions were graded as level 2 (moderate), with one case at grade 1 (mild) and one case at grade 3 (severe). Five patients experienced concomitant cutaneous adverse reactions, including 1 patient on targeted therapy, 1 on combined targeted therapy and ADC, and 3 on ICI, presenting mainly as xerosis cutis, maculopapular rash, folliculitis-like rash, and paronychia. For the 10 patients with common terminology criteria for adverse events grade 2 or higher, local administration of corticosteroids and antifungal medications were provided. Severe cases received systemic medication along with comprehensive supportive treatment. Symptoms in all patients were alleviated. Conclusions: Novel anti-tumor drugs can induce diverse oral adverse reactions, necessitating early recognition and intervention by oncologists and dentists. Through enhanced multidisciplinary collaboration and medical education, combined with local and systemic therapies, patients outcomes and qualities of life can be effectively improved.

To evaluate the associations of serum methotrexate (MTX) concentrations and MTHFR gene polymorphisms with delayed metabolism of high-dose MTX and adverse reactions in children with acute lymphoblastic leukemia (ALL).

Bacterial outer membrane vesicles (OMVs) have attracted widespread attention in the field of drug delivery due to their excellent biocompatibility, tumor penetration, and loading capacity. The anti-angiogenic peptide AP25 can block malignant tumor angiogenesis and has broad-spectrum anti-cancer activity. To achieve efficient delivery of AP25, we modified AP25 on the surface of OMVs through genetic engineering and explored their inhibitory effects on breast cancer and gastric cancer in vitro. The results indicated that the engineered OMVs had typical morphological characteristics of OMVs, and the particle size distribution conformed to the theoretical. Proteinase K digestion combined with Western blotting confirmed that AP25 was modified on the membrane surface of OMVs. Cell experiments showed that WAP25 OMVs significantly inhibited the proliferation, migration, and invasion of MDA-MB-231 and HGC-27 cells, promoted the cell apoptosis, and downregulated the expression of tumor migration and angiogenesis-related proteins: integrin beta 1 (integrin β1), Homo sapiens inhibitor of DNA binding 1 (ID1), nuclear factor kappa-B (NF-κB), and vascular endothelial growth factor (VEGF). This study achieves effective delivery of protein drugs based on OMVs for the first time, providing new ideas for the anti-angiogenesis therapy for tumors and the functional development of bacterial OMVs.